Basecamp Research, a cutting-edge AI-driven life sciences company, has recently secured a significant $60 million Series B financing round, led by Singular, bringing its total funding to $85 million. The company, which is focused on transforming the landscape of therapeutic research and development (R&D), builds sophisticated AI models on top of the world’s largest ethically sourced biological dataset. This dataset allows Basecamp to give AI the most comprehensive understanding of biology ever seen, empowering it to design complex biological systems that surpass traditional limitations. The funding will accelerate the company’s efforts to scale up its data collection and deepen its ability to offer innovative solutions to the biopharma ecosystem.
Basecamp’s AI models are foundational to their work, allowing them to generate new and deeper insights that go beyond what is currently known about biology. These insights are key to transforming therapeutic research, especially as the company collaborates with biopharma companies and academic institutions to design novel protein sequences and complex biological systems. Their AI systems become more powerful and accurate as they are exposed to more diverse biological information and context, driving performance improvements.
A key part of Basecamp Research’s success is its partnership with more than 100 biodiversity collaborators worldwide, which provides access to a rich array of biological data. These partnerships enable the company to deliver breakthroughs that have the potential to significantly impact healthcare and improve patient outcomes. In addition to this network of biodiversity partners, Basecamp recently entered a high-profile multi-year collaboration with Dr. David R. Liu’s laboratory at the Broad Institute of MIT and Harvard. Dr. Liu is a leading figure in genome editing and a Howard Hughes Medical Institute Investigator. This collaboration focuses on advancing programmable genetic medicines, with the goal of developing new approaches to treat a wide range of diseases.
Dr. Glen Gowers, co-founder and CEO of Basecamp Research, highlighted the company’s mission to tackle the fundamental data gap that has long hindered the biotech industry. He explained that Basecamp’s unique dataset, combined with its proprietary AI models, enables the company to uncover insights that human-based design cannot match. These insights, particularly in the realm of biological system design, allow Basecamp to push the boundaries of what is possible in biopharma research.
The partnership with the Liu Lab at the Broad Institute is a prime example of Basecamp’s forward-thinking approach. Together, the teams are working on developing novel fusion proteins and large molecules that could pave the way for next-generation genetic medicines. Dr. Gowers noted that combining the Liu Lab’s pioneering work in genome editing with Basecamp’s vast dataset and AI capabilities sets the stage for significant advances in therapeutic research.
Basecamp’s success in securing major funding from high-profile investors further validates its potential to reshape the life sciences industry. In addition to Singular, investors include S32, redalpine, and notable figures such as André Hoffmann (Vice-Chairman of Roche), Feike Sijbesma (Chair of Royal Philips and former CEO of DSM), and Paul Polman (former CEO of Unilever). Returning investors such as True Ventures and Hummingbird Ventures also participated in the round, demonstrating continued confidence in the company’s vision.
The Series B funds will be instrumental in expanding Basecamp Research’s data collection capabilities. The company’s existing dataset contains 100 times more advanced biological systems than the public databases typically used by pharma researchers, giving it a major advantage in the competitive biotech space. By further growing this foundational dataset, Basecamp will be able to offer even more advanced biological solutions to its biopharma partners.
Basecamp Research has already achieved success with 15 commercial bioscience partnerships across a wide range of industries, underscoring the versatility and applicability of its AI-driven biological design platform. Raffi Kamber, General Partner at Singular, expressed excitement about the company’s potential to revolutionize life sciences, noting that Basecamp’s AI models offer a “step change” in performance and a fundamental shift in how life sciences teams approach innovation.
Dr. Oliver Vince, co-founder of Basecamp Research, echoed this sentiment, emphasizing the broad scope of challenges that the company’s AI has already tackled. From designing novel biological systems to working on groundbreaking bioscience projects with global partners, Basecamp is continuously pushing the limits of what is possible in life sciences. Vince added that the company is excited by the momentum generated by its latest funding round and is eager to continue working on breakthrough projects that will redefine biological research.
As Basecamp Research continues to expand its capabilities and collaborate with leading experts and institutions, it is poised to drive significant advancements in healthcare and the life sciences. Its innovative approach to AI-driven biological design not only offers immediate benefits to its partners but also holds the potential to transform the entire biotech industry. With its Series B funding in place, Basecamp is well-positioned to scale its operations and deliver on its promise to push beyond the limits of today’s biology.